文献速递慢性肾脏病

在不同年龄人群中实施KDIGO 2024指南的实验室估算GFR

Implementing Kidney Disease: Improving Global Outcomes 2024 Through Laboratory-Estimated GFR Across Ages.
PubMed 文献 · Kidney Int Rep · 2026-01-03

研究基于PCrAGE子研究(30,104例,2-99岁)和mGFR子研究(4,144次测量),比较EKFC与2009 CKD-EPI方程在CKD分期中的差异及准确性。结果显示,从CKD-EPI转换为EKFC影响CKD分期:3.2%从II期变为III期,0.4%从III期变为IV期。在mGFR队列中,所有方程随CKD分期进展准确性下降,但EKFC在成人中始终具有最低偏倚和最高P30;CKD-EPI在18-25岁年轻成人中表现不佳,正偏倚约20 ml/min/1.73 m2且准确性降低。结论认为EKFC提供了跨全生命周期的连续稳健eGFR估算,优于CKD-EPI。

要点

  • EKFC方程适用于全年龄段,较CKD-EPI更稳健。
  • 转换方程影响CKD分期:3.2%从II期升至III期,0.4%从III期升至IV期。
  • CKD-EPI在18-25岁成人中正偏倚约20 ml/min/1.73 m2,准确性降低。

核心结论

  • EKFC方程提供跨全生命周期的连续稳健eGFR估算,优于CKD-EPI。

研究设计与样本

  • PCrAGE子研究分析30,104例2-99岁有血浆肌酐的个体;mGFR子研究使用4,144次测量评估方程性能。

主要发现

  • 在PCrAGE中,从CKD-EPI转换为EKFC影响CKD分期:3.2%从II期变为III期,0.4%从III期变为IV期。
  • 在mGFR队列中,所有方程随CKD分期进展准确性下降;EKFC在成人中始终具有最低偏倚和最高P30。
  • CKD-EPI在18-25岁年轻成人中表现不佳,正偏倚约20 ml/min/1.73 m2且准确性降低;在70岁以上老年人中各方程性能相似。

关键数值与推荐

  • KDIGO 2024指南推荐年龄适配方程,而非2009 CKD-EPI方程。
  • EKFC方程适用于所有年龄,CKD-EPI仅适用于成人,BIS1用于70岁以上。

临床怎么用

  • 临床应采用EKFC方程估算GFR以符合KDIGO 2024指南,尤其在年轻成人中避免CKD-EPI的正偏倚。
  • 转换方程可能引起CKD分期变化,需关注3.2%从II期升至III期和0.4%从III期升至IV期的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) represents a major public health issue, with early detection depending on accurate estimation of glomerular filtration rate (GFR). The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend age-adapted equations, whereas the 2009 CKD Epidemiology Collaboration (CKD-EPI) equation remains widely used in Europe despite its inapplicability in children and uncertain performance in young adults and the elderly. The objectives of this study were to compare the European Kidney Function Consortium (EKFC) and 2009 CKD-EPI equations for estimated GFR (eGFR)-based CKD staging in a general population (PCrAGE substudy), and to evaluate their performance against measured GFR (mGFR) in a reference cohort (mGFR substudy). METHODS: We analyzed data from 30,104 individuals aged 2 to 99 years with plasma creatinine (PCr) available (PCrAGE). eGFR was calculated using EKFC (all ages), CKD-EPI (adults), and Berlin Initiative Study 1 (BIS1, aged > 70 years). Performance was tested in 4144 mGFR measurements using bias and P30 across age groups and CKD stages. RESULTS: In PCrAGE, switching from CKD-EPI to EKFC impacted CKD staging (3.2% from stage II to III; 0.4% from stage III tp IV). In the mGFR cohort, all equations showed declining accuracy with advancing CKD stage. EKFC consistently had the lowest bias and highest P30 in adults. CKD-EPI performed poorly in young adults (aged 18-25 years), showing substantial positive bias (∼20 ml/min per 1.73 m2) and reduced accuracy. In older adults (aged > 70 years), performance was similar across equations. CONCLUSION: EKFC provides a continuous and robust equation for eGFR estimation across the lifespan, offering an advantage over CKD-EPI.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. De Mul A, Bres E, Bacchetta J, et al. Implementing Kidney Disease: Improving Global Outcomes 2024 Through Laboratory-Estimated GFR Across Ages. Kidney Int Rep. 2026. PMID: 41704901. doi:10.1016/j.ekir.2025.103767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。